FDA's VIP Pass for Urgent Drugs: Hearing Seeks Public Input
Published Date: 3/23/2026
Notice
Summary
The FDA is launching a pilot program called the Commissioner's National Priority Voucher (CNPV) to speed up reviews for important new drugs and treatments that tackle big U.S. health challenges. They’re inviting drug makers, experts, and the public to a hearing on June 12, 2026, to share ideas and feedback on how the program should work. This could mean faster approvals and quicker access to life-saving medicines without cutting corners.
Analyzed Economic Effects
6 provisions identified: 2 benefits, 4 costs, 0 mixed.
Ultra-fast FDA review target
The CNPV Pilot Program aims to cut FDA review times for qualifying NDAs, BLAs, and supplements from the typical 10–12 months to a target of 1–2 months. FDA also proposes a filing review target of 14–21 days after receipt of the final application component.
Priority areas that qualify
The program is limited to products that align with specified national priorities: public health crisis response; innovative breakthrough therapies; large unmet medical needs; onshoring and supply chain resilience; and affordability improvements. Only NDAs, BLAs, and manufacturing or efficacy supplements are listed as eligible application types.
Nontransferable voucher rule
CNPV vouchers are nontransferable: they cannot be sold or used for a different application, unlike some traditional priority review vouchers. The voucher grants expedited review for a single application to its recipient only.
Rapid sponsor response and meeting demands
Sponsors accepting a CNPV voucher are expected to respond rapidly to FDA information requests (typically within 24–48 hours), be available for ad hoc meetings during business hours, and facilitate inspections. Labeling negotiations are envisioned to be limited to a maximum of two rounds.
Presubmission, rolling, and submission deadlines
The program asks for presubmission meetings, rolling submissions of CMC information and proposed labeling at least 60 days before final module submission, and recommends limiting manufacturing facilities to no more than 2–3 per submission (with justification required for more). Sponsors are expected to submit a complete application within 2 years of voucher issuance and acknowledge participation or intent to redeem within 2 weeks of issuance.
Eligibility excludes most medical devices
Medical device applications are excluded from the CNPV Pilot Program, though combination products with a drug or biological product primary mode of action may be eligible. The program focuses on drug and biologic applications (NDAs and BLAs) and certain supplements.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20063, Request for Nominations for Voting Members of Food and Drug Administration Advisory Committees
The FDA is looking for smart, qualified people to join its advisory committees and help make important decisions about food and drugs. If you have the right skills, you can apply anytime, but get your nomination in by November 30, 2026, for the best chance at current openings. This is a great chance to influence public health without any cost to you!
Previous / Next Documents
Previous: 2026-05572, Foreign-Trade Zone 27; Application for Subzone; Methods Machine Tools, Inc.; Acton and Sudbury, Massachusetts
Methods Machine Tools, Inc. wants to join Foreign-Trade Zone 27 by adding two new sites in Acton and Sudbury, Massachusetts. This move could help the company save on import taxes and speed up trade, but no production changes are planned yet. Public comments are open until May 4, 2026, so now’s the time to speak up!
Next: 2026-05575, Announcement of Public Hearing
The National Commission on the Future of the Navy is holding a public hearing on March 25, 2026, to gather ideas from Congress and experts about the Navy’s future. This hearing will shape important decisions about fleet size, shipbuilding, and personnel, affecting how the Navy stays strong and ready. Anyone interested can attend or submit their thoughts by giving advance notice.